We’re tracking in-house compensation. Take the Law360 Survey
Click here
In Re Sana Biotechnology Inc Securities Litigation
-
October 17, 2025
Sana Biotechnology Inc. has asked a Seattle federal court to dismiss an investor suit over claims that it offered misleading statements regarding early clinical trials of a gene therapy, asserting that the company's disclosures were consistent with early-stage drug development risks.
-
June 03, 2025
The Rosen Law Firm PA and Pomerantz LLP will serve as co-lead counsel for shareholders accusing Seattle-based Sana Biotechnology Inc. of misleading investors about its ability to develop certain genetic therapy treatments.
-
March 24, 2025
Seattle's Sana Biotechnology Inc. is the target of a proposed class action filed on Monday by a shareholder who alleges the company misled investors about its ability to develop genetic therapy treatments for oncology and central nervous system disorders.